1. Vaddepally, R.K., Kharel, P., Pandey, R., Garje, R. & Chandra, A.B. Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence. Cancers (Basel) 12 (2020).
2. Markham, A. Dostarlimab: First Approval. Drugs 81, 1213-1219 (2021).
3. Passiglia, F. et al. Looking for the best immune-checkpoint inhibitor in pre-treated NSCLC patients: An indirect comparison between nivolumab, pembrolizumab and atezolizumab. Int J Cancer 142, 1277-1284 (2018).
4. Fessas, P., Lee, H., Ikemizu, S. & Janowitz, T. A molecular and preclinical comparison of the PD-1-targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab. Semin Oncol 44, 136-140 (2017).
5. Lee, H.T. et al. Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab. Sci Rep 7, 5532 (2017).
6. Donahue, R.N. et al. Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody. J Immunother Cancer 5, 20 (2017).
7. De Sousa Linhares, A. et al. Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling. Sci Rep 9, 11472 (2019).
8. Lepir, T. et al. Nivolumab to pembrolizumab switch induced a durable melanoma response: A case report. Medicine (Baltimore) 98, e13804 (2019).
9. Feng, D. et al. Excellent Response to Atezolizumab After Clinically Defined Hyperprogression Upon Previous Treatment With Pembrolizumab in Metastatic Triple-Negative Breast Cancer: A Case Report and Review of the Literature. Front Immunol 12, 608292 (2021).
10. Polesso, F. et al. PD-1-specific "Blocking" antibodies that deplete PD-1(+) T cells present an inconvenient variable in preclinical immunotherapy experiments. Eur J Immunol 51, 1473-1481 (2021).
11. Wu, T.D. et al. Peripheral T cell expansion predicts tumour infiltration and clinical response. Nature 579, 274-278 (2020).
12. Yost, K.E. et al. Clonal replacement of tumor-specific T cells following PD-1 blockade. Nat Med 25, 1251-1259 (2019).
13. Zhang, J. et al. Compartmental Analysis of T-cell Clonal Dynamics as a Function of Pathologic Response to Neoadjuvant PD-1 Blockade in Resectable Non-Small Cell Lung Cancer. Clin Cancer Res 26, 1327-1337 (2020).
14. Munder, P.G., Modolell, M. & Hoelzl Wallach, D.F. Cell propagation on films of polymeric fluorocarbon as a means to regulate pericellular pH and pO(2) in cultured monolayers. FEBS Lett 15, 191-196 (1971).
15. Tang, H. et al. PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression. J Clin Invest 128, 580-588 (2018).
16. Dong, H. et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8, 793-800 (2002).
17. Tu, X. et al. PD-L1 (B7-H1) Competes with the RNA Exosome to Regulate the DNA Damage Response and Can Be Targeted to Sensitize to Radiation or Chemotherapy. Mol Cell 74, 1215-1226 e1214 (2019).
18. Amir el, A.D. et al. viSNE enables visualization of high dimensional single-cell data and reveals phenotypic heterogeneity of leukemia. Nat Biotechnol 31, 545-552 (2013).
19. Polikowsky, H.G. & Drake, K.A. Supervised Machine Learning with CITRUS for Single Cell Biomarker Discovery. Methods Mol Biol 1989, 309-332 (2019).
20. Ben-Shaanan, T.L. et al. Activation of the reward system boosts innate and adaptive immunity. Nat Med 22, 940-944 (2016).
21. Brahmer, J.R. et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 28, 3167-3175 (2010).
22. Patnaik, A. et al. Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors. Clin Cancer Res 21, 4286-4293 (2015).
23. Lau, J. et al. Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice. Nat Commun 8, 14572 (2017).
24. Pearce, E.L. et al. Control of effector CD8+ T cell function by the transcription factor Eomesodermin. Science 302, 1041-1043 (2003).
25. Goldberg, M.V. et al. Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells. Blood 110, 186-192 (2007).
26. Seo, H. et al. BATF and IRF4 cooperate to counter exhaustion in tumor-infiltrating CAR T cells. Nat Immunol 22, 983-995 (2021).
27. Siddiqui, I. et al. Intratumoral Tcf1(+)PD-1(+)CD8(+) T Cells with Stem-like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy. Immunity 50, 195-211 e110 (2019).
28. Liu, X. et al. Endogenous tumor-reactive CD8(+) T cells are differentiated effector cells expressing high levels of CD11a and PD-1 but are unable to control tumor growth. Oncoimmunology 2, e23972 (2013).
29. Yan, Y. et al. CX3CR1 identifies PD-1 therapy-responsive CD8+ T cells that withstand chemotherapy during cancer chemoimmunotherapy. JCI Insight 3 (2018).
30. Zander, R. et al. CD4(+) T Cell Help Is Required for the Formation of a Cytolytic CD8(+) T Cell Subset that Protects against Chronic Infection and Cancer. Immunity 51, 1028-1042 e1024 (2019).
31. Hudson, W.H. et al. Proliferating Transitory T Cells with an Effector-like Transcriptional Signature Emerge from PD-1(+) Stem-like CD8(+) T Cells during Chronic Infection. Immunity 51, 1043-1058 e1044 (2019).
32. Ahrends, T. et al. CD4(+) T Cell Help Confers a Cytotoxic T Cell Effector Program Including Coinhibitory Receptor Downregulation and Increased Tissue Invasiveness. Immunity 47, 848-861 e845 (2017).
33. Yamauchi, T. et al. Frequency of circulating CX3CR1+CD8+T cells to predict response to immune checkpoint inhibitor therapy. Cancer Research 80 (2020).
34. Yamauchi T, H.T., Oba T, Jain V, Chen H, Attwood K, Battaglia S, George S, Chatta G, Puzanov I, Morrison C, Odunsi K, Segal BH, Dy GK, Ernstoff MS, & Ito F T-cell CX3CR1 expression as a dynamic blood-based biomarker of response to immune checkpoint inhibitors. Nature Communications 12, 1402 (2021).
35. Yamauchi, T. et al. T-cell CX3CR1 expression as a dynamic blood-based biomarker of response to immune checkpoint inhibitors. Nat Commun 12, 1402 (2021).
36. Du, X. et al. A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy. Cell Res 28, 416-432 (2018).
37. Koblish, H.K. et al. Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 Inhibitor. Cancer Discov 12, 1482-1499 (2022).
38. Johnson, R.M.G., Wen, T. & Dong, H. Bidirectional signals of PD-L1 in T cells that fraternize with cancer cells. Nat Immunol 21, 365-366 (2020).
39. Liu, X. et al. B7-H1 antibodies lose antitumor activity due to activation of p38 MAPK that leads to apoptosis of tumor-reactive CD8(+) T cells. Sci Rep 6, 36722 (2016).
40. Lucas, E.D. et al. PD-L1 Reverse Signaling in Dermal Dendritic Cells Promotes Dendritic Cell Migration Required for Skin Immunity. Cell Rep 33, 108258 (2020).
41. Kleffel, S. et al. Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth. Cell 162, 1242-1256 (2015).
42. Gibbons, R.M. et al. B7-H1 signaling is integrated during CD8(+) T cell priming and restrains effector differentiation. Cancer Immunol Immunother 63, 859-867 (2014).
43. Dammeijer, F. et al. The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes. Cancer Cell 38, 685-700 e688 (2020).
44. Oh, S.A. et al. PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancer. Nat Cancer 1, 681-691 (2020).